Jennifer Laura Labrum, PA
Physician Assistant · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 3
- Since medical school
- 17 years
- Graduated 2009
Offices
3 locations · Stanford Health Care · 3,152 clinicians in this group
Looking this up.
Hospitals listed: Stanford Health Care Tri-Valley. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Jennifer Laura Labrum’s office to ask if they take your plan before you enroll.
California Medical Board record
Licence A22350 · Cancelled
Licence status: Cancelled · since 1967 · National Autonomous University of Nicaragua Faculty of Medicine.
License has been voluntarily canceled, or the license has been expired for at least five years and has not been renewed. No practice is permitted.
Matched on the licence number without its letter prefix; check the name before relying on it.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health Care Tri-ValleyPleasanton, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Stanford Health Care, which runs 3 hospitalsPatients rate it 3 of 5 · 74% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.178, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.237, Oct 2024 – Sep 2025
See every measure and the patient survey for Stanford Health Care Tri-Valley
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 7 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.178 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.237 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.79 (0 to 1.73) · 1,041 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.79 (0.5 to 1.08) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 145.81 (96.5 to 195.12) · 72 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.9 · 55 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.6 · 92 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.5 · 96 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.5 · 395 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 391 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 162 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 1,736 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.37) · 4,425 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.22 (0.02 to 0.41) · 4,771 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.45 (1.46 to 5.44) · 1,403 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.5 (0.05 to 2.94) · 645 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.81 (0.38 to 3.24) · 1,279 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.53 (3.2 to 13.85) · 639 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.15 (1.89 to 8.41) · 648 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.14 to 3.07) · 370 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.16 (0 to 0.83) · 4,160 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 74 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.369 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.112 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.1 · 110 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.1 · 437 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -5.8 · 94 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -19.3 · 456 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -0.3 · 402 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 15.8 · 358 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.8 (4.7 to 9.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.1 (7.5 to 13.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.9 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.3 · 92 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.4 (9.6 to 16.2) · 1,532 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.2) · 929 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,268 patients answered, 26% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 65% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 42% |
| "YES", patients would definitely recommend the hospital | 74% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
Original Medicare doctor bills
$97,103
Medicare paid this office $97,103 for 249 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Hyaluronan or derivative, durolane, for intra-articular injection, 1 mg | 103 | $51,090 | None |
| Aspiration and/or injection of fluid from large joint | 195 | $20,414 | $58 |
| Short return visit (20+ min) | 79 | $7,061 | $66 |
| Return visit (30+ min) | 29 | $2,809 | $97 |
| Short return visit | 48 | $2,167 | $42 |
See all 8 services
| Hyaluronan or derivative, durolane, for intra-articular injection, 1 mg | 103 | $51,090 | None |
| Aspiration and/or injection of fluid from large joint | 195 | $20,414 | $58 |
| Short return visit (20+ min) | 79 | $7,061 | $66 |
| Return visit (30+ min) | 29 | $2,809 | $97 |
| Short return visit | 48 | $2,167 | $42 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 128 | $699 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 115 | $69 | None |
| Injection, bupivicaine, not otherwise specified, 0.5 mg | 95 | $35 | None |
Procedures Medicare counted
| Upper limb (arm) arthroscopy (minimally invasive joint repair) | 25 | More than 69% of doctors who do this |
Procedures year by year
| Procedure | 2017 | 2018 | 2019 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Aspiration and/or injection of fluid from large joint | 70 | 27 | – | 36 | 226 | 350 |
| Repair of shoulder rotator cuff using an endoscope | – | – | – | – | 13 | – |
Times billed to Original Medicare each year. A blank year means fewer than 11 people had it, or none: Medicare does not publish smaller counts. Medicare Advantage patients are not included.
Who their Medicare patients are
249 Original Medicare patients in 2024. Average age 75 · Women 59% · Also on Medicaid 7% · Health risk score 1.01. At or below the middle of the specialty; the typical physician assistant clinician is at 1.31.
Conditions among them: High blood pressure 65% · Chronic kidney disease 24% · Coronary heart disease 21% · Atrial fibrillation 21% · Diabetes 20% · Depression 18% · Cancer 13% · Heart failure 10% · COPD 9% · Stroke 4%.
The office billed $1,210,131, Medicare allowed $127,418 and paid $97,103; for 16,673 services of 27 kinds; $60,970 of it was for drugs given in the office and $36,132 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 249 | 16,673 | 75 | 1.01 | $1,210,131 | $97,103 |
| 2023 | 263 | 7,939 | 74 | 1.03 | $721,216 | $72,099 |
| 2022 | 73 | 1,390 | 73 | 0.84 | $141,085 | $16,030 |
| 2019 | 32 | 103 | 71 | 0.96 | $67,143 | $4,788 |
| 2018 | 51 | 436 | 76 | 1.09 | $48,939 | $9,320 |
| 2017 | 103 | 1,458 | 72 | 1.32 | $124,980 | $19,902 |
| 2016 | 87 | 1,492 | 73 | 1.12 | $130,928 | $20,511 |
| 2015 | 86 | 903 | 74 | 0.98 | $166,700 | $15,138 |
| 2014 | 86 | 261 | 72 | 1.04 | $246,496 | $16,504 |
| 2013 | 52 | 143 | 69 | 1.10 | $254,873 | $10,898 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 9 services
| Hyaluronan or derivative, durolane, for intra-articular injection, 1 mg | 64 | $29,242 | None |
| Aspiration and/or injection of fluid from large joint | 156 | $12,511 | $55 |
| Short return visit (20+ min) | 70 | $6,197 | $70 |
| Return visit (30+ min) | 53 | $5,212 | $93 |
| New patient visit (30+ min) | 58 | $4,640 | $80 |
| Short return visit | 82 | $4,257 | $43 |
| Repair of shoulder rotator cuff using an endoscope | 13 | $1,724 | $133 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 92 | $463 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 83 | $46 | None |
2022: 5 services
| Hyaluronan or derivative, durolane, for intra-articular injection, 1 mg | 14 | $7,525 | None |
| New patient visit (30+ min) | 27 | $2,379 | $88 |
| Aspiration and/or injection of fluid from large joint | 33 | $1,996 | $55 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 13 | $55 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 12 | $6 | None |
2018: 5 services
| Return visit (30+ min) | 15 | $1,239 | $83 |
| Aspiration and/or injection of fluid from large joint | 23 | $1,223 | $45 |
| Short return visit (20+ min) | 16 | $771 | $48 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 14 | $90 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 14 | $5 | None |
2017: 6 services
| Hyaluronan or derivative, synvisc or synvisc-one, for intra-articular injection, 1 mg | 12 | $7,968 | None |
| Aspiration and/or injection of fluid from large joint | 50 | $3,222 | $46 |
| Short return visit (20+ min) | 39 | $2,192 | $51 |
| Return visit (30+ min) | 23 | $2,090 | $80 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 37 | $293 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 37 | $15 | None |
2016: 6 services
| Hyaluronan or derivative, synvisc or synvisc-one, for intra-articular injection, 1 mg | 21 | $10,871 | None |
| Aspiration and/or injection of fluid from large joint | 40 | $2,089 | $43 |
| Short return visit (20+ min) | 24 | $1,521 | $51 |
| Return visit (30+ min) | 18 | $1,442 | $80 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 23 | $152 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 22 | $8 | None |
2015: 5 services
| Aspiration and/or injection of fluid from large joint | 26 | $1,483 | $45 |
| Short return visit (20+ min) | 23 | $1,166 | $51 |
| Return visit (30+ min) | 15 | $1,153 | $77 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 19 | $117 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 16 | $8 | None |
2014: 4 services
| Short return visit (20+ min) | 32 | $1,938 | $54 |
| Return visit (30+ min) | 21 | $1,791 | $78 |
| New patient visit (45+ min) | 12 | $1,485 | $124 |
| X-ray of lower and sacral spine, 2-3 views | 24 | $729 | $29 |
2013: 2 services
| Partial removal of spine bone with release of lower spinal cord and/or nerves, 1 segment | 13 | $1,401 | $108 |
| Short return visit (20+ min) | 18 | $1,223 | $56 |
Drugs they prescribed that Part D paid
$13,481
Pharmacies billed $13,481 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 45% of their Part D prescriptions (223 of 498) in 2024. A higher opioid share than 9 in 10 peers; the typical physician assistant clinician is at 1%.
484 generic and 14 brand-name prescriptions · $13,481 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Ambien | 13 | $7,847 | $604 |
| Celecoxib | 11 | $1,124 | $102 |
| Hydrocodone-Acetaminophen | 67 | $658 | $10 |
| Oxycodone-Acetaminophen | 45 | $484 | $11 |
| Diclofenac | 59 | $469 | $8 |
See all 13 drugs
| Ambien | 13 | $7,847 | $604 |
| Celecoxib | 11 | $1,124 | $102 |
| Hydrocodone-Acetaminophen | 67 | $658 | $10 |
| Oxycodone-Acetaminophen | 45 | $484 | $11 |
| Diclofenac | 59 | $469 | $8 |
| Oxycodone | 56 | $354 | $6 |
| Gabapentin | 38 | $344 | $9 |
| Diclofenac | 11 | $155 | $14 |
| Tramadol | 51 | $129 | $3 |
| Methylprednisolone | 19 | $121 | $6 |
| Meloxicam | 15 | $120 | $8 |
| Ibuprofen | 21 | $85 | $4 |
| Ondansetron | 13 | $68 | $5 |
Year by year
| 2024 | 498 | 165 | 45% (223) | 3% | $13,481 |
| 2023 | 567 | 200 | 42% (239) | 2% | $15,438 |
| 2022 | 402 | 150 | 42% (167) | 9% | $16,414 |
| 2021 | 322 | 126 | 52% (167) | 11% | $11,450 |
| 2020 | 154 | 72 | 48% (74) | None | $2,641 |
| 2019 | 82 | 40 | 89% (73) | None | $1,708 |
| 2018 | 68 | 34 | 78% (53) | 0% | $1,609 |
| 2017 | 147 | 54 | 91% (133) | 0% | $3,136 |
| 2016 | 152 | 63 | 86% (131) | None | $4,561 |
| 2015 | 135 | 50 | 86% (116) | None | $4,405 |
| 2014 | 73 | 41 | 51% (37) | None | $2,572 |
| 2013 | 127 | 54 | 54% (69) | 9% | $4,184 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 15 drugs
| Ambien | 11 | $7,795 | $709 |
| Naloxone | 16 | $1,278 | $80 |
| Celecoxib | 24 | $785 | $33 |
| Gabapentin | 61 | $737 | $12 |
| Hydrocodone-Acetaminophen | 86 | $702 | $8 |
| Oxycodone-Acetaminophen | 51 | $665 | $13 |
| Diclofenac | 39 | $490 | $13 |
| Oxycodone | 57 | $412 | $7 |
| Pregabalin | 11 | $177 | $16 |
| Cyclobenzaprine | 15 | $174 | $12 |
| Methylprednisolone | 17 | $173 | $10 |
| Amoxicillin | 22 | $152 | $7 |
| Meloxicam | 22 | $115 | $5 |
| Tramadol | 37 | $111 | $3 |
| Ibuprofen | 21 | $98 | $5 |
2022: 11 drugs
| Pradaxa | 11 | $4,387 | $399 |
| Narcan | 20 | $2,891 | $145 |
| Naloxone | 17 | $1,127 | $66 |
| Diclofenac | 27 | $786 | $29 |
| Ondansetron Odt | 50 | $641 | $13 |
| Hydrocodone-Acetaminophen | 57 | $616 | $11 |
| Oxycodone | 73 | $579 | $8 |
| Amoxicillin | 41 | $315 | $8 |
| Celecoxib | 11 | $258 | $23 |
| Hydromorphone | 18 | $172 | $10 |
| Tramadol | 13 | $72 | $6 |
2021: 7 drugs
| Narcan | 13 | $1,990 | $153 |
| Oxycodone | 79 | $674 | $9 |
| Ondansetron Odt | 41 | $624 | $15 |
| Hydrocodone-Acetaminophen | 44 | $434 | $10 |
| Amoxicillin | 31 | $241 | $8 |
| Hydromorphone | 24 | $222 | $9 |
| Oxycodone-Acetaminophen | 12 | $116 | $10 |
2020: 5 drugs
| Diclofenac | 13 | $459 | $35 |
| Oxycodone | 36 | $310 | $9 |
| Hydrocodone-Acetaminophen | 12 | $293 | $24 |
| Ondansetron Odt | 23 | $225 | $10 |
| Amoxicillin | 13 | $110 | $8 |
2019: 2 drugs
| Hydrocodone-Acetaminophen | 33 | $754 | $23 |
| Oxycodone-Acetaminophen | 25 | $680 | $27 |
2018: 2 drugs
| Hydrocodone-Acetaminophen | 29 | $905 | $31 |
| Oxycodone-Acetaminophen | 12 | $421 | $35 |
2017: 2 drugs
| Hydrocodone-Acetaminophen | 98 | $1,930 | $20 |
| Oxycodone-Acetaminophen | 26 | $818 | $31 |
2016: 2 drugs
| Hydrocodone-Acetaminophen | 96 | $2,828 | $29 |
| Oxycodone-Acetaminophen | 17 | $754 | $44 |
2015: 2 drugs
| Hydrocodone-Acetaminophen | 83 | $2,709 | $33 |
| Oxycodone-Acetaminophen | 20 | $1,013 | $51 |
2014: 2 drugs
| Hydrocodone-Acetaminophen | 27 | $759 | $28 |
| Gabapentin | 13 | $181 | $14 |
2013: 3 drugs
| Hydrocodone-Acetaminophen | 44 | $805 | $18 |
| Oxycodone Hcl-Acetaminophen | 12 | $668 | $56 |
| Gabapentin | 24 | $258 | $11 |
Money from drug and device companies
$35 in 2024
| 2024 | 2 | 2 | None | $35 |
| 2022 | 1 | 3 | None | $98 |
| 2021 | 1 | 3 | None | $72 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Evolution Surgical | None | $18 | 1 payment
|
| Merck Sharp & Dohme | Bridion | $17 | 1 payment
|
See all 2 published payments
| Evolution Surgical | Meals · 2024-11-12 | None | $18 |
| Merck Sharp & Dohme | Meals · 2024-06-26 | Bridion | $17 |
See earlier years (2022, 2021)
2022: $98
| Boston Scientific | General - Io Ablation | $98 | 3 payments
|
2021: $72
| Boston Scientific | Truselect | $72 | 3 payments
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1154655504
- Licence
- CA 22350California A22350: Cancelled
- Group
- Stanford Health Care
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Physician assistant (363A00000X); Physician assistant, surgical (363AS0400X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2009-10-01
- NPI last updated
- 2025-12-24
- NPI record certified
- 2025-12-24
This is when the NPI record was last certified, not a medical board exam.
This office lists an electronic records connection.